Reduction of temporomandibular joint pain after treatment with a combination of methotrexate and infliximab is associated with changes in synovial fluid and plasma cytokines in rheumatoid arthritis

Cells Tissues Organs

Volumn 180, Issue 1, 2005, Pages 22-30

  Kopp, Sigvard ^a   Alstergren, Per ^a   Ernestam, Sofia ^b   Nordahl, Silvi ^a   Morin, Pär ^a   Bratt, Johan ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cytokines; Infliximab; Pain; Rheumatoid arthritis; Temporomandibular joint

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONFERENCE PAPER; DRUG DETERMINATION; DRUG EFFECT; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; JOINT FUNCTION; MALE; MANDIBLE; MYOFASCIAL PAIN; PAIN ASSESSMENT; PAIN THRESHOLD; PALPATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; TEMPOROMANDIBULAR JOINT; VEIN BLOOD FLOW;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYTOKINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PAIN; PROSPECTIVE STUDIES; SYNOVIAL FLUID; TEMPOROMANDIBULAR JOINT DISORDERS;

EID: 23844485917     PISSN: 14226405     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086195     Document Type: Conference Paper

References (23)

1. Alstergren, P., C. Benavente, S. Kopp (2003) Interleukin-1beta, interleukin-1 receptor antagonist, and interleukin-1 soluble receptor II in temporomandibular joint synovial fluid from patients with chronic polyarthritides. J Oral Maxillofac Surg 61: 1171-1178.
2. Alstergren, P., S. Kopp (1997) Pain and synovial fluid concentration of serotonin in arthritic temporomandibular joints. Pain 72: 137-143.
3. Alstergren, P., S. Kopp, E. Theodorsson (1999) Synovial fluid sampling from the temporomandibular joint: sample quality criteria and levels of interleukin-1 beta and serotonin. Acta Odontol Scand 57: 16-22.
4. Arnett, F.C., S.M. Edworthy, D.A. Bloch, D.J. McShane, J.F. Fries, N.S. Cooper, L.A. Healey, S.R. Kaplan, M.H. Liang, H.S. Luthra, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324.
5. Charles, P., M.J. Elliott, D. Davis, A. Potter, J.R. Kalden, C. Antoni, F.C. Breedveld, J.S. Smolen, G. Eberl, K. deWoody, M. Feldmann, R.N. Maini (1999) Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 163: 1521-1528.
6. Dinarello, C.A. (1998) Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 16: 457-499.
7. Duff, G.W. (1994) Cytokines and acute phase proteins in rheumatoid arthritis. Scand J Rheumatol Suppl 100: 9-19.
8. Elliott, M.J., R.N. Maini, M. Feldmann, J.R. Kalden, C. Antoni, J.S. Smolen, B. Leeb, F.C. Breedveld, J.D. Macfarlane, H. Bijl (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105-1110.
9. Jouvenne, P., E. Vannier, C.A. Dinarello, P. Miossec (1998) Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis: correlations with markers of inflammation and joint destruction. Arthritis Rheum 41: 1083-1089.
10. Lipsky, P.E., D.M. van der Heijde, E.W. St Clair, D.E. Furst, F.C. Breedveld, J.R. Kalden, J.S. Smolen, M. Weisman, P. Emery, M. Feldmann, G.R. Harriman, R.N. Maini (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343: 1594-1602.
11. Maini, R., E.W. St Clair, F. Breedveld, D. Furst, J. Kalden, M. Weisman, J. Smolen, P. Emery, G. Harriman, M. Feldmann, P. Lipsky (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354: 1932-1939.
12. Maini, R.N., F.C. Breedveld, J.R. Kalden, J.S. Smolen, D. Davis, J.D. Macfarlane, C. Antoni, B. Leeb, M.J. Elliott, J.N. Woody, T.F. Schaible, M. Feldmann (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41: 1552-1563.
13. Miller, L.C., E.A. Lynch, S. Isa, J.W. Logan, C.A. Dinarello, A.C. Steere (1993) Balance of synovial fluid IL-1 beta and IL-1 receptor antagonist and recovery from Lyme arthritis [see comments]. Lancet 341: 146-148.
14. Moreland, L.W. (1999) Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol 26: 7-15.
15. Niedel, J., M. Schulze, J. Lindshau (1995) Association between degree of bone-erosion and synovial fluid-levels of tumor necrosis factor alpha in the knee-joints of patients with rheumatoid arthritis. Inflamm Res 44: 217-221.
16. Nordahl, S., P. Alstergren, S. Kopp (2000) Tumor necrosis factor-alpha in synovial fluid and plasma from patients with chronic connective tissue disease and its relation to temporomandibular joint pain. J Oral Maxillofac Surg 58: 525-530.
17. Rosengren, S., G.S. Firestein, D.L. Boyle (2003) Measurement of inflammatory biomarkers in synovial tissue extracts by enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 10: 1002-1010.
18. Samols, D., A. Agrawal, I. Kushner (2002) Acute phase proteins; in Oppenheim, J.J., M. Feldmann (eds): Cytokine Reference. Amsterdam, Elsevier Science, pp 1-16.
19. Taiwo, Y.O., J.D. Levine (1992) Serotonin is a directly-acting hyperalgesic agent in the rat. Neuroscience 48: 485-490.
20. Tegelberg, A., S. Kopp (1987) Clinical findings in the stomatognathic system for individuals with rheumatoid arthritis and osteoarthrosis. Acta Odontol Scand 45: 65-75.
21. van de Loo, A.A., O.J. Arntz, A.C. Bakker, P.L. van Lent, M.J. Jacobs, W.B. van den Berg (1995) Role of interleukin 1 in antigen-induced exacerbations of murine arthritis. Am J Pathol 146: 239-249.
22. Voog, U., P. Alstergren, S. Eliasson, E. Leibur, R. Kallikorm, S. Kopp (2004) Progression of radiographic changes in the temporomandibular joints of patients with rheumatoid arthritis in relation to inflammatory markers and mediators in the blood. Acta Odontol Scand 62: 7-13.
23. Watkins, L.R., E.P. Wiertelak, L.E. Goehler, K.P. Smith, D. Martin, S.F. Maier (1994) Characterization of cytokine-induced hyperalgesia. Brain Res 654: 15-26.